With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells.
BioIntron has expressed thousands bispecific antibodies in 2020 with extensive experience in bispecific antibody production. BioIntron can perform any format bispecific antibody production requested by our client.
